BTIG reaffirms Buy on ArriVent BioPharma with $29 target

what happened

BTIG analysts reaffirmed their Buy rating on ArriVent BioPharma shares and kept the price target at $29. The bank's target implies roughly 72.7% upside from the October 15 close of $16.79. According to the note, the company's outlook rests on its lead candidate firmonertinib, which has shown activity across several EGFR mutations in non-small cell lung cancer, and on its next-generation antibody-drug conjugates, including ARR-217.

The note also lists recent analyst actions: HC Wainwright & Co maintained Buy with a $27 target (October 8), Guggenheim maintained Buy with an $18 target (October 7), and BTIG maintained Buy with a $29 target (October 7). Across the three most recent notes over the past 30 days, price targets range from $18 to $29. Data is provided by Benzinga via TradingView.

why it matters

Routine rating confirmations like this typically concern a single company and rarely move the broader market. For biotech investors, the more important factor is how the company's clinical data develops, while the spread in price targets shows analysts disagree on the stock's valuation.

tags

instruments